HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3

Yin,Fufen; Wang,Ning; Wang,Shanshan; Yu,Fengsheng; Sun,Xin; Yu,Xiao; Luo,Bing; Zhao,Chengquan; Wang,Yankui

doi:10.3892/or.2017.5465

HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3

Authors:
- Fufen Yin
- Ning Wang
- Shanshan Wang
- Fengsheng Yu
- Xin Sun
- Xiao Yu
- Bing Luo
- Chengquan Zhao
- Yankui Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, P.R. China, Department of Obstetrics and Gynecology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Obstetrics and Gynecology, People's Hospital of Huangdao District, Qingdao, Shandong 266000, P.R. China, Department of Medical Microbiology, Qingdao University Medical College, Qingdao, Shandong 266000, P.R. China, Department of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-3180, USA
Published online on: February 17, 2017 https://doi.org/10.3892/or.2017.5465
Pages: 2324-2334

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Both human papillomavirus (HPV) infection and the aberrant Ras associated domain family gene 1A (RASSF1A) promoter methylation status participate in the pathogenesis of cervical cancer. Some studies suggest that E6, and E7 are involved in the pathogenetic mechanisms of RASSF1A. We mainly explored a possible involvement of HPV16 oncogenes E6 or/and E7 in RASSF1A promoter methylation status and possible roles of RASSF1A gene methylation in cervical cancer. Bisulfite genomic sequencing (BGS) PCR combined with TA clone, methylation-specific PCR (MSP) were used to analyze methylation status of the RASSF1A gene promoter in HPV16/18-positive and HPV-negative cervical cancer cell lines; ectopically expressed HPV16 E6, E7 and E6/E7 cervical cancer cell lines; normal cervical and cervical cancer tissues. The mRNA and protein expression of RASSF1A was detected by RT-PCR and western blotting. Re-expression and downregulated promoter methylation status were detected in the ectopically expressed HPV16 E6 and E7 cervical cancer cell line HT-3. The methylation status and expression of RASSF1A could be downregulated or reactivated by 5-Aza-dc in HT-3 and C33A cells. Additionally, statistics showed significant hypermethylation of RASSF1A in cervical cancer samples compared to that in normal cervical samples (P<0.05). The false negative rate (FNR) was 6.25% by HC2 method, when reconfirmed by HPV detection combining the MY09/11, GP5+/6+ and SPF1/2 methods. The ectopic expression of HPV16 E6 and/or E7 may be involved in aberrant methylation and expression of the RASSF1A gene. RASSF1A gene expression could be regulated by its promoter methylation status. Additionally, the false negativity of the HPV detection may contribute to the uncertain relationship between HPV infection and aberrant RASSF1A promoter methylation.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Feinberg AP and Tycko B: The history of cancer epigenetics. Nat Rev Cancer. 4:143–153. 2004. View Article : Google Scholar : PubMed/NCBI
3	zur Hausen H: Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 49:4677–4681. 1989.PubMed/NCBI
4	Kitchener HC, Denton K, Soldan K and Crosbie EJ: Developing role of HPV in cervical cancer prevention. BMJ. 347:f47812013. View Article : Google Scholar : PubMed/NCBI
5	Ajiro M and Zheng ZM: E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78. MBio. 6:e02068–e14. 2015. View Article : Google Scholar : PubMed/NCBI
6	Narisawa-Saito M and Kiyono T: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci. 98:1505–1511. 2007. View Article : Google Scholar : PubMed/NCBI
7	Flatley JE, McNeir K, Balasubramani L, Tidy J, Stuart EL, Young TA and Powers HJ: Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. Cancer Epidemiol Biomarkers Prev. 18:2782–2789. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ostör AG: Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol. 12:186–192. 1993. View Article : Google Scholar : PubMed/NCBI
9	Neyaz MK, Kumar RS, Hussain S, Naqvi SH, Kohaar I, Thakur N, Kashyap V, Das BC, Husain SA and Bharadwaj M: Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers. 13:597–606. 2008. View Article : Google Scholar : PubMed/NCBI
10	Baylin SB: The cancer epigenome: Its origins, contributions to tumorigenesis, and translational implications. Proc Am Thorac Soc. 9:64–65. 2012. View Article : Google Scholar : PubMed/NCBI
11	Xiong J, Li Y, Huang K, Lu M, Shi H, Ma L, Luo A, Yang S, Lu Z, Zhang J, et al: Association between DAPK1 promoter methylation and cervical cancer: A meta-analysis. PLoS One. 9:e1072722014. View Article : Google Scholar : PubMed/NCBI
12	Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, Lee H, Choi N, Kim J, Kim H, et al: The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol. 6:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
13	Shivakumar L, Minna J, Sakamaki T, Pestell R and White MA: The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 22:4309–4318. 2002. View Article : Google Scholar : PubMed/NCBI
14	Agathanggelou A, Cooper WN and Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 65:3497–3508. 2005. View Article : Google Scholar : PubMed/NCBI
15	Whang YM, Kim YH, Kim JS and Yoo YD: RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res. 65:3682–3690. 2005. View Article : Google Scholar : PubMed/NCBI
16	Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens S, Jonas U and Serth J: RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer. 6:492007. View Article : Google Scholar : PubMed/NCBI
17	Gao T, Wang S, He B, Pan Y, Song G, Gu L, Chen L, Nie Z, Xu Y and Li R: The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: A systematic review and meta-analysis. PLoS One. 7:e483002012. View Article : Google Scholar : PubMed/NCBI
18	Hagrass HA, Pasha HF, Shaheen MA, Bary Abdel EH and Kassem R: Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep. 41:57–65. 2014. View Article : Google Scholar : PubMed/NCBI
19	Malpeli G, Amato E, Dandrea M, Fumagalli C, Debattisti V, Boninsegna L, Pelosi G, Falconi M and Scarpa A: Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. BMC Cancer. 11:3512011. View Article : Google Scholar : PubMed/NCBI
20	Wu K, Xu XN, Chen Y, Pu XL, Wang BY and Tang XD: RASSF1A gene methylation is associated with nasopharyngeal carcinoma risk in Chinese. Asian Pac J Cancer Prev. 16:2283–2287. 2015. View Article : Google Scholar : PubMed/NCBI
21	Maliukova AV, Loginov VI, Khodyrev DS, Kadyrova EL, Pronina IV, Ivanova TA, Kiselev FL, Zabarovskiĭ NP and Braga EA: Methylation of the putative tumor suppressor gene, RASSF1A, in primary cervical tumors. Mol Biol (Mosk). 38:1005–1013. 2004.(In Russian). PubMed/NCBI
22	Pfeifer GP and Dammann R: Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 70:576–583. 2005. View Article : Google Scholar : PubMed/NCBI
23	Li JY, Huang T, Zhang C, Jiang DJ, Hong QX, Ji HH, Ye M and Duan SW: Association between RASSF1A promoter hypermethylation and oncogenic HPV infection status in invasive cervical cancer: A meta-analysis. Asian Pac J Cancer Prev. 16:5749–5754. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kuzmin I, Liu L, Dammann R, Geil L, Stanbridge EJ, Wilczynski SP, Lerman MI and Pfeifer GP: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res. 63:1888–1893. 2003.PubMed/NCBI
25	Muñoz J, Inda MM, Lázcoz P, Zazpe I, Fan X, Alfaro J, Tuñón T, Rey JA and Castresana JS: Promoter methylation of RASSF1A associates to adult secondary glioblastomas and pediatric glioblastomas. ISRN Neurol. 2012:5765782012.PubMed/NCBI
26	Shukla S, Bharti AC, Mahata S, Hussain S, Hedau S, Sharma R, Pillai MR, Krishna S, Chiplunkar S, Tongaonkar H, et al: Application of a multiplex PCR to cervical cells collected by a paper smear for the simultaneous detection of all mucosal human papillomaviruses (HPVs) and typing of high-risk HPV types 16 and 18. J Med Microbiol. 59:1303–1310. 2010. View Article : Google Scholar : PubMed/NCBI
27	Lee SH, Vigliotti VS, Vigliotti JS and Pappu S: Validation of human papillomavirus genotyping by signature DNA sequence analysis. BMC Clin Pathol. 9:32009. View Article : Google Scholar : PubMed/NCBI
28	Gal-Yam EN, Saito Y, Egger G and Jones PA: Cancer epigenetics: Modifications, screening, and therapy. Annu Rev Med. 59:267–280. 2008. View Article : Google Scholar : PubMed/NCBI
29	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
30	Paschos K and Allday MJ: Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol. 18:439–447. 2010. View Article : Google Scholar : PubMed/NCBI
31	Woodman CB, Collins SI and Young LS: The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer. 7:11–22. 2007. View Article : Google Scholar : PubMed/NCBI
32	Meng W, Huebner A, Shabsigh A, Chakravarti A and Lautenschlaeger T: Combined RASSF1A and RASSF2A promoter methylation analysis as diagnostic biomarker for bladder cancer. Mol Biol Int. 2012:7018142012. View Article : Google Scholar : PubMed/NCBI
33	Senchenko VN, Kisseljova NP, Ivanova TA, Dmitriev AA, Krasnov GS, Kudryavtseva AV, Panasenko GV, Tsitrin EB, Lerman MI, Kisseljov FL, et al: Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer. Epigenetics. 8:409–420. 2013. View Article : Google Scholar : PubMed/NCBI
34	Cohen Y, Singer G, Lavie O, Dong SM, Beller U and Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res. 9:2981–2984. 2003.PubMed/NCBI
35	Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW, Lo KW and To KF: Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer. 105:204–209. 2003. View Article : Google Scholar : PubMed/NCBI
36	Guo W, Cui L, Wang C, Guo Y, Shen S, Kuang G and Dong Z: Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma. Clin Exp Metastasis. 31:521–533. 2014. View Article : Google Scholar : PubMed/NCBI
37	Numoto K, Yoshida A, Sugihara S, Kunisada T, Morimoto Y, Yoneda Y, Fujita Y, Nishida K, Ouchida M and Ozaki T: Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines. J Cancer Res Clin Oncol. 136:17–25. 2010. View Article : Google Scholar : PubMed/NCBI
38	Borden EC: Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: Potential application to melanoma. Cytokine Growth Factor Rev. 18:491–501. 2007. View Article : Google Scholar : PubMed/NCBI
39	Deshpande R, Mansara P and Kaul-Ghanekar R: Alpha-linolenic acid regulates Cox2/VEGF/MAP kinase pathway and decreases the expression of HPV oncoproteins E6/E7 through restoration of p53 and Rb expression in human cervical cancer cell lines. Tumour Biol. 37:3295–3305. 2016. View Article : Google Scholar : PubMed/NCBI
40	Shaikh F, Sanehi P and Rawal R: Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV. Bioinformation. 8:607–612. 2012. View Article : Google Scholar : PubMed/NCBI
41	Farthing AJ and Vousden KH: Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol. 2:170–174. 1994. View Article : Google Scholar : PubMed/NCBI
42	Naryshkin S and Austin RM: Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening. Drug Healthc Patient Saf. 4:167–172. 2012. View Article : Google Scholar : PubMed/NCBI
43	Nocon M, Roll S, Mittendorf T, von der Schulenburg JM and Willich SN: Human papilloma virus (HPV) testing for cervical carcinoma screening. Z Evid Fortbild Qual Gesundhwes. 104:138–142. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
44	Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, et al: Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 9:R572007. View Article : Google Scholar : PubMed/NCBI
45	Honda S, Haruta M, Sugawara W, Sasaki F, Ohira M, Matsunaga T, Yamaoka H, Horie H, Ohnuma N, Nakagawara A, et al: The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer. 123:1117–1125. 2008. View Article : Google Scholar : PubMed/NCBI
46	Lai HC, Lin YW, Chang CC, Wang HC, Chu TW, Yu MH and Chu TY: Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol. 104:629–635. 2007. View Article : Google Scholar : PubMed/NCBI